Drug Trial Radar · NCT05580510
" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "
Last checked: Nov 20, 2026Latest source record: Nov 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
160
Planned (sponsor's estimate)
Start
Feb 6, 2023
Primary completion
Jul 28, 2023
Study completion Mar 29, 2024
Sponsor
- Lead sponsor
- Instituto Nacional de Cardiologia Ignacio ChavezAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Boehringer Ingelheim
- First posted
- Oct 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The treatment of adult patients with congenital heart disease (ACHD) and heart failure (HF) represents a great challenge since, to date, there is no standardized guideline for this specific population. Although new treatments for HF have been proposed, such as Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors and neprilisin and angiotensin receptor inhibitors, the benefit of these drugs in patients with HF associated with congenital heart disease in adults has not yet been demonstrated. For this reason, this study pretends to evaluate the efficacy of empagliflozin and sacubitril/valsartan in this population.
Conditions
- Congenital Heart Disease
- Heart Failure
- Heart Failure With Reduced Ejection Fraction
Interventions
Sacubitril 49 MG / Valsartan 51 MG [Entresto] BIDDrug
This group of patients will receive the conventional treatment of heart failure according to the "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure" and Sacubitril/Valsartan as an active comparator.
Empagliflozin 10 MG ODDrug
This group of patients will receive the conventional treatment of heart failure according to the "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure" and Empagliflozin as an experimental drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 3D echocardiographic systemic ventricular end-diastolic volume indexTime frame: Twelve weeks
- 3D echocardiographic systemic ventricular end-systolic volume indexTime frame: Twelve weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institute of Cardiology Ignacio Chavez
Mexico City, Mexico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.